Open AccessCHRONIC DEMYELINIZING POLYNEUROPATHY: ETIOPATHOGENETIC, CLINICAL ASPECTS, MODERN DIRECTIONS OF MEDICAL THERAPY
Author(s) -
A. V. Meshcheryakova,
A. Vorobyova
Publication year - 2021
Publication title -
nacionalʹnaâ associaciâ učënyh/nacionalʹnaâ associaciâ učenyh
Language(s) - English
Resource type - Journals
eISSN - 2782-2869
pISSN - 2413-5291
DOI - 10.31618/nas.2413-5291.2021.1.67.423
Subject(s) - rituximab , medicine , chronic inflammatory demyelinating polyneuropathy , polyneuropathy , quality of life (healthcare) , medical therapy , intensive care medicine , immunology , physical therapy , antibody , nursing
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder of the peripheral nervous system. The article discusses the practical experience of using off label therapy with rituximab in the complex treatment of a patient with a progressive course of chronic inflammatory demyelinating polyneuropathy. Due to the ineffectiveness of standard therapy, the option of treatment with genetically engineered drugs (rituximab) was considered. The use of rituximab contributed to the achievement of positive dynamics and an improvement in the patient's quality of life.